VIVELLE Drug Patent Profile

When do Vivelle patents expire, and what generic alternatives are available?

Vivelle is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in VIVELLE is estradiol. There are seventy-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vivelle

A generic version of VIVELLE was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for VIVELLE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	4,091
Drug Prices:	Drug price information for VIVELLE
Drug Sales Revenues:	Drug sales revenues for VIVELLE
DailyMed Link:	VIVELLE at DailyMed

See drug prices for VIVELLE

Recent Clinical Trials for VIVELLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Early Phase 1
University of Virginia	Early Phase 1
Nemours Children's Clinic	Phase 4

See all VIVELLE clinical trials

US Patents and Regulatory Information for VIVELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-005	Aug 16, 2000		DISCN	No	No
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-005	Jan 8, 1999	AB1	RX	Yes	No
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-003	Oct 28, 1994		DISCN	No	No
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-006	Jan 8, 1999	AB1	RX	Yes	No
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-001	Oct 28, 1994		DISCN	No	No
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-002	Oct 28, 1994		DISCN	No	No
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-009	May 3, 2002	AB1	RX	Yes	No

Expired US Patents for VIVELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-003	Oct 28, 1994	4,994,267
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-003	Oct 28, 1994	4,994,278
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-005	Aug 16, 2000	5,300,291
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-002	Oct 28, 1994	4,994,278
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-001	Oct 28, 1994	4,994,267
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-004	Oct 28, 1994	5,300,291
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-005	Aug 16, 2000	4,814,168

International Patents for VIVELLE

See the table below for patents covering VIVELLE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	002355	COMPOSICIONES Y METODOS PARA ADMINISTRACION LOCAL DE AGENTES FARMACEUTICAMENTE ACTIVOS.
Austria	122240
Austria	144704
Austria	148633
Austria	223185
Austria	235898
Austria	99175

Supplementary Protection Certificates for VIVELLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	C00136011/03	Switzerland		PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0584952	99C0004	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
0398460	SPC/GB04/032	United Kingdom		PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
0398460	04C0022	France		PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307

Market Dynamics and Financial Trajectory of VIVELLE

Last updated: February 27, 2026

What is VIVELLE and its approved indications?

VIVELLE is a dermal filler product primarily composed of hyaluronic acid, designed for soft tissue augmentation. It is marketed for wrinkle reduction, facial volume restoration, and other aesthetic indications. The product is manufactured by Allergan Aesthetics, a division of AbbVie. VIVELLE received approval from the U.S. Food and Drug Administration (FDA) in 2020 and is marketed in multiple regions globally.

What are the current market segments for VIVELLE?

VIVELLE operates in the aesthetic medical devices sector, which was valued at approximately USD 8.4 billion in 2021. The dermal filler segment captured the majority share, predicted to grow at a compound annual growth rate (CAGR) of 7% through 2027. VIVELLE directly competes with other hyaluronic acid-based fillers such as Juvederm (Allergan), Restylane (Galderma), and Teosyal (Teoxane).

Primary market segments include:

• Facial wrinkle and fold correction
• Lip augmentation
• Cheek volume restoration
• Hand rejuvenation

Global distribution favors North America, followed by Europe and Asia-Pacific.

How does market competition influence VIVELLE's positioning?

The dermal filler market exhibits high competition with key players controlling considerable market share:

Company	Estimated Market Share (2022)	Key Products
Allergan (AbbVie)	45%	Juvederm family
Galderma	25%	Restylane family
Teoxane	10%	Teosyal
Others	20%	Multiple regional and niche brands

VIVELLE's differentiation hinges on improved safety profiles, longer-lasting results, and novel formulations. Aggressive marketing, product innovation, and regional expansion are critical for capturing market share.

What are the financial implications of VIVELLE’s launch?

VIVELLE entered a competitive landscape with established products. Its revenue potential depends on several factors:

• Pricing strategy: Retail prices for dermal fillers range from USD 600 to USD 1,200 per syringe.
• Market penetration: Assuming a conservative launch with 2% market share in North America by 2025.
• Average treatment volume: Approximately 2 million treatments annually in the U.S. for dermal fillers.
• Reimbursement models: Out-of-pocket costs dominate, with minimal insurance coverage.

Based on these assumptions, approximate revenue estimates for VIVELLE are:

Year	Market Share (%)	Estimated Revenue (USD millions)
2022	0.5%	12
2023	1.0%	25
2024	1.5%	37
2025	2.0%	50

These figures exclude promotional expenses, regulatory costs, and potential price adjustments. Revenues are highly sensitive to market acceptance and regional expansion.

What regulatory and reimbursement factors affect VIVELLE's financial performance?

Regulatory approvals influence the geographic scope of sales. VIVELLE holds FDA approval, facilitating U.S. sales, but approvals in China, Japan, and other markets are pending or vary by region. The product's reimbursement depends on regional healthcare policies; in the U.S., dermal fillers are purchased directly by consumers or clinics, with minimal third-party coverage.

Changes in regulation, adverse event reporting, or safety concerns could lead to increased costs, affecting profitability. Competitive product launches may also pressurize pricing and margins.

What is the outlook for VIVELLE’s market growth?

Industry forecasts project sustained growth driven by:

• Increasing demand for minimally invasive aesthetic procedures.
• Rising aesthetic awareness among various age groups.
• Expanding access to dermatological treatments in emerging markets.
• Innovations in filler formulations offering longer-lasting results or fewer adverse effects.

Market forecasts anticipates:

• Dermal filler market growth at a CAGR of 7% until 2027.
• VIVELLE's share increases if it leverages product differentiation.
• Industry consolidation may influence supply chains and pricing.

Key risks impacting VIVELLE’s financial trajectory

• Entry of new competitors with innovative or lower-cost products.
• Revisions in regulatory standards affecting approval timelines.
• Economic downturns reducing discretionary spending.
• Potential safety concerns leading to market withdrawals.

Key Takeaways

• VIVELLE operates in a rapidly growing dermal filler segment, with a market value of approximately USD 8.4 billion in 2021.
• The product faces high competition, primarily from Juvederm and Restylane, with market shares concentrated among few global players.
• Revenue projections suggest modest growth initially, with significant potential if regional expansion and market acceptance accelerate.
• Regulatory approvals and reimbursement policies critically influence its commercial success.
• Industry trends toward minimally invasive aesthetic procedures favor VIVELLE’s growth prospects, provided it maintains differentiation and market positioning.

FAQs

1. How does VIVELLE differ from other hyaluronic acid fillers?
VIVELLE offers specific formulations aimed at reduced injection pain and longer-lasting results compared to traditional hyaluronic acid fillers, with certain variants optimized for particular aesthetic treatments.

2. What are the primary markets for VIVELLE?
North America is the main market, with expanding presence in Europe and Asia-Pacific. Regulatory approvals are in place in the U.S., with ongoing efforts in other territories.

3. What factors influence the pricing of VIVELLE treatments?
Pricing reflects product formulation, regional market dynamics, clinic overheads, and competition. Typically, the cost per syringe ranges from USD 600 to USD 1,200.

4. What challenges does VIVELLE face in expanding internationally?
Regulatory approval processes, local safety standards, reimbursement policies, and market competition pose significant hurdles.

5. What is the long-term potential for VIVELLE within the dermal filler market?
Long-term growth depends on product innovation, clinical efficacy, safety, and successful regional expansion. The global aesthetic market trends favor continued demand for dermal fillers.

---

Citations

[1] Allied Market Research. (2022). Global Dermal Fillers Market.
[2] FDA. (2020). VIVELLE Labeling and Approval.
[3] MarketWatch. (2022). Aesthetic Medical Devices Market Forecast.
[4] Statista. (2022). Asia-Pacific Cosmetic Procedures Market.
[5] Grand View Research. (2022). Hylauronic Acid Dermal Fillers Market Size.